Forte Biosciences, Inc. (FBRX) Notes Payables (2016 - 2020)
Forte Biosciences (FBRX) has disclosed Notes Payables for 5 consecutive years, with $5.0 million as the latest value for Q1 2020.
- On a quarterly basis, Notes Payables rose 126.0% to $5.0 million in Q1 2020 year-over-year; TTM through Mar 2020 was $5.0 million, a 126.0% increase, with the full-year FY2019 number at $4.7 million, changed N/A from a year prior.
- Notes Payables was $5.0 million for Q1 2020 at Forte Biosciences, up from $4.7 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $27.8 million in Q3 2019 to a low of $2.2 million in Q1 2019.
- A 5-year average of $7.9 million and a median of $7.2 million in 2016 define the central range for Notes Payables.
- Peak YoY movement for Notes Payables: tumbled 69.39% in 2019, then soared 126.0% in 2020.
- Forte Biosciences' Notes Payables stood at $7.2 million in 2016, then changed by 0.0% to $7.2 million in 2017, then changed by 0.0% to $7.2 million in 2018, then tumbled by 34.11% to $4.7 million in 2019, then rose by 5.0% to $5.0 million in 2020.
- Per Business Quant, the three most recent readings for FBRX's Notes Payables are $5.0 million (Q1 2020), $4.7 million (Q4 2019), and $27.8 million (Q3 2019).